English EN Spanish ES French FR Chinese (Simplified) ZH-CN
Print Friendly, PDF & Email

NCT/Study#

NCT03288545 /

SGN22E-002

A Study Of Enfortumab Vedotin (ASG-22CE) As Monotherapy Or In Combination With Other Anticancer Therapies For The Treatment Of Urothelial Cancer

DISEASE GROUP:
Genito-Urinary
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: